In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum.

Abstract

The antibacterial activity of BMY-28142, a new aminothiazole cephalosporin, was measured by standardized broth microdilution and agar dilution methods against 450 gram-positive and gram-negative bacteria isolated from pediatric infections, including acute pulmonary exacerbations of cystic fibrosis. BMY-28142 activity was compared with that of aminoglycosides, beta-lactams, chloramphenicol, trimethoprim-sulfamethoxazole, vancomycin, and clindamycin. The activity of BMY-28142 in combination with other antimicrobial agents against Pseudomonas aeruginosa was also determined. Furthermore, the effects of inoculum and pH on BMY-28142 activity were evaluated. BMY-21842 was active against most of the gram-positive and gram-negative isolates, with the exception of methicillin-resistant Staphylococcus aureus and Pseudomonas cepacia. The combination of BMY-28142 with tobramycin was often synergistic, and combinations of BMY-28142 with either polymyxin B or imipenem were usually antagonistic. BMY-28142 antibacterial activity could be adversely affected at extremes of medium pH and by high inoculum densities.

Statistics

050100'88'91'94'97'00'03'06'09'12'15
Citations per Year

171 Citations

Semantic Scholar estimates that this publication has 171 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Conrad1985InVA, title={In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum.}, author={Dennis A Conrad and R K Scribner and Allen H. Weber and Melvin I . Marks}, journal={Antimicrobial agents and chemotherapy}, year={1985}, volume={28 1}, pages={58-63} }